Application No.: 10/699,987-Conf. #5359 2 Docket No.: 025444.1059-US02

AMENDMENTS TO THE CLAIMS

Claims 1-72 (Cancelled).

73. (Currently amended) A solid composition comprising an anti-allergic effective amount of desloratedine in a free base form and a desloratedine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein at least 80% of the desloratedine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

74. (Cancelled)

75. (Currently amended) A solid composition comprising an anti-allergic effective amount of desloratedine in a free base form and a desloratedine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein about 0.1% to about 10% of at least one pharmaceutically acceptable antioxidant is present.

76-79. (Cancelled)

- 80. (Currently amended) A solid composition comprising an anti-allergic effective amount of desloratedine in a free base form and a desloratedine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein the total amount of desloratedine degradation products in the solid composition is less than or equal to 2% by weight, wherein at least 80% of the desloratedine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.
- 81. (Currently amended) A solid composition comprising an anti-allergic effective amount of desloratedine in a free base form and a desloratedine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein the total amount of desloratedine degradation products in the solid composition is less than or equal to 2% by weight, wherein about 0.1% to about 10% of at least one pharmaceutically acceptable antioxidant is present.

82-89. (Cancelled)

90. (Currently amended) A solid composition comprising about 5 mg of desloratedine in a free base form and a desloratedine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein the total amount of desloratedine degradation products in the solid composition is less than or equal to 2% by weight, wherein at least 80% of the desloratedine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

91-92. (Cancelled)

93. (Previously presented) A solid composition whose ingredients comprise:

INGREDIENT	mg/composition
Desloratadine, micronized	5.0
Corn Starch NF/Ph. Eur.	36.0
Microcrystalline Cellulose NF/Ph. Eur./JP	132.7
Edetate Disodium USP	10.0
Citric Acid Anhydrous, USP	10.0
Stearic Acid, NF.	6.0
Dye	0.3
TOTAL	200.0

wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.

94. (Previously presented) The solid composition of claim 93 wherein at least 80% of the desloratedine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

95. (Previously presented) A solid composition whose ingredients comprise:

INGREDIENT	mg/composition
Desloratadine, micronized	2.5
Corn Starch NF/Ph. Eur.	18.0
Microcrystalline Cellulose NF/Ph. Eur./JP	66.35
Edetate Disodium	5.0
Citric Acid	5.0

Application No.: 10/699,987-Conf. #5359 4 Docket No.: 025444.1059-US02

Stearic Acid USP/Ph. Eur. 3.0

Dye 0.15

TOTAL 100.00

and wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.

96. (Previously presented) The solid composition of claim 95 wherein at least 80% of the desloratedine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

97. (Cancelled)

98. (Cancelled)

99. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 75.

100. (Cancelled)

101. (Currently amended) A solid composition comprising an anti-allergic effective amount of desloratedine in a free base form and a desloratedine-protective amount of two pharmaceutically acceptable antioxidants, wherein the total amount of desloratedine degradation products in the solid composition is less than or equal to 2% by weight, wherein the two pharmaceutically acceptable antioxidants are edetate disodium and citric acid.

102-104. (Cancelled)

105. (Currently amended) A solid composition comprising about 2.5 mg desloratedine in a free base form and a desloratedine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein at least 80% of the desloratedine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

106. (Previously presented) A solid composition whose ingredients comprise:

INGREDIENT	mg/composition
Desloratadine, micronized	5.0
Corn Starch NF/Ph. Eur.	36.0
Microcrystalline Cellulose NF/Ph. Eur./JP	140.7
Edetate Disodium	10.0
Citric Acid	2.0
Talc NF/Ph. Eur.	6.0
Dye	0.3
TOTAL	200.0

wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.

107. (Previously presented) The solid composition of claim 106 wherein at least 80% of the desloratedine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

108. (Previously presented) A solid composition whose ingredients comprise:

INGREDIENT	mg/composition
Desloratadine, micronized	2.5
Corn Starch NF/Ph. Eur.	18.0
Microcrystalline Cellulose NF/Ph. Eur./JP	70.35
Edetate Disodium	5.0
Citric Acid	1.0
Talc NF/Ph. Eur.	3.0
Dye	0.28
TOTAL	100.00

wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.

109. (Previously presented) The solid composition of claim 108 wherein at least 80% of the desloratedine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

Application No.: 10/699,987-Conf. #5359 6 Docket No.: 025444.1059-US02

110-116. (Cancelled)

117. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 101.

118. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 105.

119. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 106.

120. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 108.

121. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 73.